{"id":"gemcitabine-alone","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"10-30","effect":"Rash"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"10-20","effect":"Dyspnea"},{"rate":"<1","effect":"Hemolytic uremic syndrome (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly to its active triphosphate form. It inhibits ribonucleotide reductase, reducing deoxyribonucleotide pools, and is incorporated into DNA during replication, leading to chain termination and apoptosis. It is particularly effective against rapidly dividing cells.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:52.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Pancreatic cancer"},{"name":"Bladder cancer"},{"name":"Breast cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT03907475","phase":"PHASE2","title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-16","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":115},{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT07259317","phase":"PHASE2","title":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2026-01-27","conditions":"Adenocarcinoma, Carcinoma, Pancreatic Ductal","enrollment":60},{"nctId":"NCT02595892","phase":"PHASE2","title":"Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-08-25","conditions":"Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":70},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07492225","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-08-15","conditions":"Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma","enrollment":120},{"nctId":"NCT04216316","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-14","conditions":"Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":12},{"nctId":"NCT06282575","phase":"PHASE3","title":"Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-07-19","conditions":"Biliary Tract Cancer","enrollment":286},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT07392541","phase":"PHASE1, PHASE2","title":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Carcinoma","enrollment":29},{"nctId":"NCT02690558","phase":"PHASE2","title":"Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-05","conditions":"Bladder Cancer","enrollment":39},{"nctId":"NCT04658862","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-07","conditions":"Urinary Bladder Neoplasms","enrollment":518},{"nctId":"NCT04823897","phase":"PHASE1","title":"A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours","status":"RECRUITING","sponsor":"PharmaMatrix Holdings Ltd","startDate":"2021-07-26","conditions":"Cancer: Recurrent and/or Metastatic Solid Tumours","enrollment":70},{"nctId":"NCT07107750","phase":"PHASE1","title":"Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma","enrollment":48},{"nctId":"NCT04559139","phase":"PHASE2, PHASE3","title":"Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8","enrollment":186},{"nctId":"NCT07480850","phase":"PHASE2","title":"Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":40},{"nctId":"NCT04657068","phase":"PHASE1, PHASE2","title":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Artios Pharma Ltd","startDate":"2021-01-27","conditions":"Advanced Cancer, Metastatic Cancer, Ovarian Cancer","enrollment":442},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT07477418","phase":"PHASE1, PHASE2","title":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms","enrollment":10},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT07476443","phase":"PHASE2, PHASE3","title":"Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-04-20","conditions":"Nephrotoxicity","enrollment":75},{"nctId":"NCT07223047","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-25","conditions":"Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":252},{"nctId":"NCT03547973","phase":"PHASE2","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2018-08-13","conditions":"Metastatic Urothelial Cancer","enrollment":827},{"nctId":"NCT07475234","phase":"PHASE1, PHASE2","title":"Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Xiuchao Wang","startDate":"2026-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06319820","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-18","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":641},{"nctId":"NCT03732677","phase":"PHASE3","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-16","conditions":"Muscle Invasive Bladder Cancer","enrollment":1063},{"nctId":"NCT04640623","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-18","conditions":"Urinary Bladder Neoplasms","enrollment":220},{"nctId":"NCT07468851","phase":"PHASE1, PHASE2","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2026-06-10","conditions":"High-risk Non-muscle-invasive Bladder Cancer","enrollment":180},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT07471165","phase":"PHASE2","title":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Locally Advanced Perihilar Cholangiocarcinoma","enrollment":25},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT03003962","phase":"PHASE3","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-01-02","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":669},{"nctId":"NCT04832854","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":50},{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT07191418","phase":"NA","title":"Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Roberto Valente","startDate":"2026-03","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":178},{"nctId":"NCT03036098","phase":"PHASE3","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-24","conditions":"Urothelial Cancer","enrollment":1314},{"nctId":"NCT05502250","phase":"PHASE2","title":"Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2023-07-14","conditions":"Hodgkin Lymphoma","enrollment":75},{"nctId":"NCT07254091","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2026-01-30","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT07000084","phase":"PHASE3","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-07-17","conditions":"Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":330},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT06624085","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-28","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT04127227","phase":"PHASE2","title":"Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-10-09","conditions":"NK/T Cell Lymphoma Nos","enrollment":34},{"nctId":"NCT06457503","phase":"PHASE4","title":"A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2024-11-01","conditions":"Nasopharyngeal Cancer Recurrent","enrollment":100},{"nctId":"NCT07049055","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","status":"RECRUITING","sponsor":"Engeneic Pty Limited","startDate":"2026-01-12","conditions":"Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":144},{"nctId":"NCT07433673","phase":"PHASE2","title":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2026-08","conditions":"Colon and Rectal Cancer","enrollment":20},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04605913","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT06960577","phase":"PHASE3","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-15","conditions":"Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate","enrollment":150},{"nctId":"NCT06059261","phase":"PHASE2","title":"Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2026-02-09","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT06972615","phase":"PHASE2","title":"Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy","status":"NOT_YET_RECRUITING","sponsor":"BLATAM","startDate":"2026-04-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":37},{"nctId":"NCT07411144","phase":"PHASE2","title":"Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2020-03-15","conditions":"Diffuse Pleural Mesothelioma (DPM)","enrollment":64},{"nctId":"NCT05945732","phase":"","title":"DESTINY Breast Respond HER2-low Europe","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-10-24","conditions":"Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer","enrollment":1155},{"nctId":"NCT03233139","phase":"PHASE1","title":"Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-06-21","conditions":"Advanced Malignancies","enrollment":146},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT05430698","phase":"PHASE2","title":"PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-01-31","conditions":"Perihilar Cholangiocarcinoma","enrollment":62},{"nctId":"NCT06015659","phase":"PHASE2","title":"ZN-c3 + Gemcitabine in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brandon Huffman, MD","startDate":"2023-11-16","conditions":"Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":12},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Non-Small Cell Lung Cancer","enrollment":1280},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT05616624","phase":"PHASE1, PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-05","conditions":"Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer","enrollment":31},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06528093","phase":"PHASE1","title":"A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":8},{"nctId":"NCT03682068","phase":"PHASE3","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":1246},{"nctId":"NCT03661320","phase":"PHASE3","title":"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-06","conditions":"Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer","enrollment":855},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT05300282","phase":"PHASE1, PHASE2","title":"Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-02-27","conditions":"Relapsed or Refractory Hodgkin's Lymphoma","enrollment":122},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT03967977","phase":"PHASE3","title":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2019-05-29","conditions":"Urothelial Carcinoma","enrollment":420},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06048133","phase":"PHASE2","title":"Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)","status":"RECRUITING","sponsor":"Nataliya Uboha","startDate":"2024-03-08","conditions":"Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer","enrollment":33},{"nctId":"NCT07364305","phase":"PHASE2","title":"HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-01-01","conditions":"ICC, Advanced Cancer","enrollment":50},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT04733027","phase":"EARLY_PHASE1","title":"First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2021-05-18","conditions":"Metastatic Solid Tumor Cancer","enrollment":57},{"nctId":"NCT06519370","phase":"PHASE3","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-08-09","conditions":"Triple Negative Breast Cancer","enrollment":350},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT06576635","phase":"NA","title":"LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-16","conditions":"NSCLC","enrollment":29},{"nctId":"NCT07351591","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":88},{"nctId":"NCT03943667","phase":"PHASE3","title":"Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2019-05-23","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":211},{"nctId":"NCT05524168","phase":"PHASE2","title":"SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-25","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT06855225","phase":"PHASE2","title":"A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Mehmet Akce","startDate":"2026-03","conditions":"Combined Hepatocellular and Cholangiocarcinoma","enrollment":29},{"nctId":"NCT05668884","phase":"PHASE2","title":"GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-10-18","conditions":"Biliary Tract Carcinoma","enrollment":93},{"nctId":"NCT06790602","phase":"PHASE2","title":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-01","conditions":"Pancreatic Ductal Adenocarcinoma (mPDAC)","enrollment":43},{"nctId":"NCT05852717","phase":"PHASE2","title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Dipenkumar Modi","startDate":"2023-10-31","conditions":"Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer","enrollment":32},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":"Carcinoma, Non-Small -Cell Lung","enrollment":300},{"nctId":"NCT06076837","phase":"PHASE1","title":"The Seven Trial: Exploiting the Unfolded Protein Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2025-01-09","conditions":"Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic","enrollment":6},{"nctId":"NCT07333287","phase":"PHASE2","title":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2026-02-01","conditions":"Pancreatic Cancer Liver Metastases, Immunotherapy-naive","enrollment":38},{"nctId":"NCT07325539","phase":"PHASE2","title":"LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer","enrollment":55},{"nctId":"NCT07328802","phase":"PHASE2","title":"Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"ORR,OS,PFS","enrollment":25},{"nctId":"NCT02989584","phase":"PHASE1, PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-12-20","conditions":"Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma","enrollment":54},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":505},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT03364530","phase":"PHASE2","title":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2018-06-11","conditions":"Cholangiocarcinoma Non-resectable, Non-metastatic","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemzar"],"phase":"phase_3","status":"active","brandName":"Gemcitabine alone","genericName":"Gemcitabine alone","companyName":"Intergroupe Francophone de Cancerologie Thoracique","companyId":"intergroupe-francophone-de-cancerologie-thoracique","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death. Used for Non-small cell lung cancer, Pancreatic cancer, Bladder cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}